ES2616442T3 - Formulación encapsulada - Google Patents

Formulación encapsulada Download PDF

Info

Publication number
ES2616442T3
ES2616442T3 ES13778029.2T ES13778029T ES2616442T3 ES 2616442 T3 ES2616442 T3 ES 2616442T3 ES 13778029 T ES13778029 T ES 13778029T ES 2616442 T3 ES2616442 T3 ES 2616442T3
Authority
ES
Spain
Prior art keywords
ravuconazole
capsule shell
derivative
mass
phosphonooxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13778029.2T
Other languages
English (en)
Spanish (es)
Inventor
Yosuke Ueki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of ES2616442T3 publication Critical patent/ES2616442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13778029.2T 2012-04-20 2013-04-17 Formulación encapsulada Active ES2616442T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012097055 2012-04-20
JP2012097055 2012-04-20
PCT/JP2013/061418 WO2013157584A1 (ja) 2012-04-20 2013-04-17 カプセル剤

Publications (1)

Publication Number Publication Date
ES2616442T3 true ES2616442T3 (es) 2017-06-13

Family

ID=49383539

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13778029.2T Active ES2616442T3 (es) 2012-04-20 2013-04-17 Formulación encapsulada

Country Status (16)

Country Link
US (1) US9981040B2 (ko)
EP (1) EP2839835B1 (ko)
JP (1) JP6181044B2 (ko)
KR (1) KR102044734B1 (ko)
CN (1) CN104254334B (ko)
AU (1) AU2013250251B2 (ko)
CA (1) CA2869882C (ko)
ES (1) ES2616442T3 (ko)
HK (1) HK1206989A1 (ko)
MY (1) MY168430A (ko)
NZ (1) NZ700800A (ko)
PH (1) PH12014502148B1 (ko)
RU (1) RU2642934C2 (ko)
SG (1) SG11201406097SA (ko)
TW (1) TWI574705B (ko)
WO (1) WO2013157584A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104324381B (zh) * 2014-09-29 2017-01-18 湖南尔康制药股份有限公司 一种具保湿能力的淀粉胶囊及其制备方法
WO2019106571A1 (en) * 2017-11-28 2019-06-06 Roivant Sciences Gmbh Dosing regimens for the treatment of fungal infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2959423B2 (ja) 1994-12-01 1999-10-06 シオノギクオリカプス株式会社 カプセル用皮膜組成物
JP2001170137A (ja) 1999-12-16 2001-06-26 Shionogi Qualicaps Kk 硬質カプセル及びその製造方法
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
DE10012063A1 (de) * 2000-03-14 2001-09-20 Basf Ag Weichkapseln enthaltend Polymerisate von Vinylestern und Polyethern, deren Verwendung und Herstellung
US7887838B2 (en) 2002-01-18 2011-02-15 Banner Pharmacaps, Inc. Non-gelatin film and method and apparatus for producing same
CN1713901A (zh) * 2002-11-22 2005-12-28 卫材株式会社 填充了替普瑞酮的羟丙基甲基纤维素胶囊制剂
CN101389333A (zh) * 2006-02-22 2009-03-18 卫材R&D管理有限公司 稳定化药物组合物
NZ575714A (en) 2006-10-06 2011-05-27 Toyama Chemical Co Ltd Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent
JP2008189585A (ja) * 2007-02-02 2008-08-21 Qualicaps Co Ltd 水溶性硬質カプセル剤
EP2108677A1 (de) 2008-04-10 2009-10-14 Swiss Caps Rechte und Lizenzen AG Thermoplastische Stärkemassen

Also Published As

Publication number Publication date
TWI574705B (zh) 2017-03-21
KR102044734B1 (ko) 2019-11-15
AU2013250251A1 (en) 2014-10-23
EP2839835A4 (en) 2015-12-02
CN104254334A (zh) 2014-12-31
RU2642934C2 (ru) 2018-01-29
AU2013250251B2 (en) 2017-05-11
CA2869882A1 (en) 2013-10-24
JP6181044B2 (ja) 2017-08-16
PH12014502148A1 (en) 2014-12-01
TW201402156A (zh) 2014-01-16
EP2839835B1 (en) 2016-12-21
EP2839835A1 (en) 2015-02-25
US20150118299A1 (en) 2015-04-30
US9981040B2 (en) 2018-05-29
NZ700800A (en) 2016-06-24
KR20140146096A (ko) 2014-12-24
SG11201406097SA (en) 2014-11-27
PH12014502148B1 (en) 2014-12-01
CA2869882C (en) 2019-09-10
JPWO2013157584A1 (ja) 2015-12-21
CN104254334B (zh) 2017-10-13
RU2014140343A (ru) 2016-06-10
WO2013157584A1 (ja) 2013-10-24
HK1206989A1 (en) 2016-01-22
MY168430A (en) 2018-11-09

Similar Documents

Publication Publication Date Title
US11077086B2 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
EP2986289B1 (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
JP2007537258A5 (ko)
JPWO2007102242A1 (ja) 外用の医薬組成物
JP2013100317A5 (ko)
EP2269648A2 (de) Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
EP2700404A1 (en) Antcin derivatives in combination with an anti-cancer drug in treatment and/or prevention of tumors
JP2010527347A5 (ko)
JP2013522230A5 (ko)
JP2013509395A5 (ko)
ES2616442T3 (es) Formulación encapsulada
CN108024995A (zh) 包含塞来昔布及曲马多的药剂学组合物
JP2014521641A5 (ko)
IL254641B2 (en) Methods and preparations including naproxen and fexofenamide for relieving symptoms of dizziness associated with alcohol consumption
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
ES2337848T3 (es) Formulaciones de valsartan.
JP2005516945A (ja) アゼチジン誘導体に基づく医薬組成物
RU2016103764A (ru) Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан
JP2002114686A (ja) 点眼剤組成物
JP2014510150A (ja) 心筋梗塞後の患者の心不全および不整脈を処置するためのａ２ｂアデノシン受容体アンタゴニストの使用
AR046213A1 (es) Forma de presentacion del naproxeno sodico
CN105412077B (zh) 一种丁苯酞的新用途
JP2008508257A (ja) 禁煙のための組成物および方法